Mesna Overdose: Clinical Perspective
Mesna can be overdosed, but there is no known antidote and the drug demonstrates a remarkably favorable safety profile even at doses substantially exceeding standard recommendations.
Evidence from Overdose Cases
The FDA drug label provides the most direct evidence regarding mesna overdose 1. In clinical trials, patients received intravenous mesna at doses ranging from 10 mg/kg to 66 mg/kg per day for 3-5 days (in combination with ifosfamide or cyclophosphamide). The adverse reactions observed were:
- Nausea
- Vomiting
- Diarrhea
- Fever
An increased rate of these adverse reactions occurred in patients receiving ≥80 mg/kg per day compared to those receiving lower doses 1.
Postmarketing Overdose Data
In postmarketing surveillance, administration of 4.5 g to 6.9 g of mesna resulted in hypersensitivity reactions including 1:
- Mild hypotension
- Shortness of breath
- Asthma exacerbation
- Rash
- Flushing
Dose-Escalation Studies
Research demonstrates mesna's wide therapeutic window. In phase I dose-escalation trials, patients received ifosfamide doses up to 18 g/m² with equivalent mesna dosing (up to 18 g/m²) 2, 3. The dose-limiting toxicity at these extreme doses was renal insufficiency from ifosfamide, not mesna toxicity 2. This indicates that mesna itself has substantial safety margins even at very high doses.
Standard Dosing Context
For perspective, standard mesna dosing equals 60-100% of the ifosfamide dose (typically 8-12 g/m² per cycle), administered as either 4:
- Three IV bolus doses (20% before, 40% at 4h, 40% at 8h after ifosfamide)
- IV-oral-oral regimen (20% IV before, 40% oral at 2h and 6h)
Clinical Management of Suspected Overdose
There is no specific antidote for mesna overdose 1. Management is supportive:
- Monitor for hypersensitivity reactions (hypotension, bronchospasm, rash)
- Provide symptomatic treatment for gastrointestinal symptoms
- Observe for respiratory symptoms, particularly in patients with underlying asthma
- Supportive care with IV fluids and antiemetics as needed
Important Caveats
- The toxicity profile in overdose cases primarily reflects gastrointestinal and hypersensitivity reactions rather than organ-threatening toxicity
- Most reported overdoses occurred in the context of concurrent chemotherapy administration, making it difficult to attribute all adverse effects solely to mesna
- Benzyl alcohol preservative in multi-dose vials poses additional risk in neonates and low-birth-weight infants, but this is a preservative issue rather than mesna toxicity 1
Bottom Line
While mesna overdose is possible and can cause uncomfortable symptoms (primarily GI distress and hypersensitivity reactions), the drug has demonstrated safety even at doses many-fold higher than standard recommendations. The absence of a specific antidote is clinically acceptable given the self-limited nature of overdose symptoms and the lack of life-threatening toxicity in reported cases.